CH545783A - Novel indole derivs - prepn by reacting 4-(2-hydroxy-3-isopropylaminopropoxy) indoles and acid anhy-drides - Google Patents
Novel indole derivs - prepn by reacting 4-(2-hydroxy-3-isopropylaminopropoxy) indoles and acid anhy-dridesInfo
- Publication number
- CH545783A CH545783A CH18271A CH545783DA CH545783A CH 545783 A CH545783 A CH 545783A CH 18271 A CH18271 A CH 18271A CH 545783D A CH545783D A CH 545783DA CH 545783 A CH545783 A CH 545783A
- Authority
- CH
- Switzerland
- Prior art keywords
- formula
- group
- acid
- compounds
- isopropylaminopropoxy
- Prior art date
Links
- 150000008065 acid anhydrides Chemical class 0.000 title claims description 4
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 title description 12
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 title description 6
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 title description 6
- JZQKKSLKJUAGIC-UHFFFAOYSA-N pindolol Chemical class CC(C)NCC(O)COC1=CC=CC2=C1C=CN2 JZQKKSLKJUAGIC-UHFFFAOYSA-N 0.000 title 1
- 239000002253 acid Substances 0.000 claims abstract description 12
- -1 1,1-dimethyl-2-propynyl Chemical group 0.000 claims abstract description 11
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 10
- 150000003839 salts Chemical class 0.000 claims abstract description 10
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract description 8
- 125000004965 chloroalkyl group Chemical group 0.000 claims abstract description 6
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims abstract description 3
- 125000003884 phenylalkyl group Chemical group 0.000 claims abstract description 3
- 150000001875 compounds Chemical class 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 claims description 5
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 4
- 239000000460 chlorine Substances 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- XMSZANIMCDLNKA-UHFFFAOYSA-N methyl hypofluorite Chemical compound COF XMSZANIMCDLNKA-UHFFFAOYSA-N 0.000 claims description 4
- 125000001424 substituent group Chemical group 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 150000007513 acids Chemical class 0.000 claims description 2
- 229940054051 antipsychotic indole derivative Drugs 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 150000002475 indoles Chemical class 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 238000011282 treatment Methods 0.000 abstract description 4
- 150000008064 anhydrides Chemical class 0.000 abstract description 3
- 230000003288 anthiarrhythmic effect Effects 0.000 abstract description 2
- 230000000903 blocking effect Effects 0.000 abstract description 2
- 208000029078 coronary artery disease Diseases 0.000 abstract description 2
- 238000011321 prophylaxis Methods 0.000 abstract description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 102000012740 beta Adrenergic Receptors Human genes 0.000 abstract 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 abstract 1
- 230000033764 rhythmic process Effects 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- NOGFHTGYPKWWRX-UHFFFAOYSA-N 2,2,6,6-tetramethyloxan-4-one Chemical compound CC1(C)CC(=O)CC(C)(C)O1 NOGFHTGYPKWWRX-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 239000005711 Benzoic acid Substances 0.000 description 4
- 235000010233 benzoic acid Nutrition 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-M oxalate(1-) Chemical compound OC(=O)C([O-])=O MUBZPKHOEPUJKR-UHFFFAOYSA-M 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 239000012280 lithium aluminium hydride Substances 0.000 description 3
- QGWACZFSCSTOCG-UHFFFAOYSA-N 2-methyl-4-phenylmethoxy-1h-indole Chemical compound C1=CC=C2NC(C)=CC2=C1OCC1=CC=CC=C1 QGWACZFSCSTOCG-UHFFFAOYSA-N 0.000 description 2
- LJFVSIDBFJPKLD-UHFFFAOYSA-N 4-phenylmethoxy-1h-indole Chemical class C=1C=CC=2NC=CC=2C=1OCC1=CC=CC=C1 LJFVSIDBFJPKLD-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000005956 quaternization reaction Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- MRUDNSFOFOQZDA-UHFFFAOYSA-N 2,6-dichlorobenzoic acid Chemical compound OC(=O)C1=C(Cl)C=CC=C1Cl MRUDNSFOFOQZDA-UHFFFAOYSA-N 0.000 description 1
- RILLZYSZSDGYGV-UHFFFAOYSA-N 2-(propan-2-ylamino)ethanol Chemical compound CC(C)NCCO RILLZYSZSDGYGV-UHFFFAOYSA-N 0.000 description 1
- 125000005809 3,4,5-trimethoxyphenyl group Chemical group [H]C1=C(OC([H])([H])[H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 1
- PJAHEELREUZCCQ-UHFFFAOYSA-N 3-methyl-4-phenylmethoxy-1h-indole Chemical class C=12C(C)=CNC2=CC=CC=1OCC1=CC=CC=C1 PJAHEELREUZCCQ-UHFFFAOYSA-N 0.000 description 1
- IPLKGJHGWCVSOG-UHFFFAOYSA-N 4-chlorobutanoic acid Chemical compound OC(=O)CCCCl IPLKGJHGWCVSOG-UHFFFAOYSA-N 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- NFJBQIZTZRJFEQ-UHFFFAOYSA-N 4-phenylmethoxy-1h-indole-2-carbonyl chloride Chemical compound C1=CC=C2NC(C(=O)Cl)=CC2=C1OCC1=CC=CC=C1 NFJBQIZTZRJFEQ-UHFFFAOYSA-N 0.000 description 1
- 108060003345 Adrenergic Receptor Proteins 0.000 description 1
- 102000017910 Adrenergic receptor Human genes 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 238000006683 Mannich reaction Methods 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000005902 aminomethylation reaction Methods 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000006264 debenzylation reaction Methods 0.000 description 1
- 125000005265 dialkylamine group Chemical group 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000001834 epinephrinelike Effects 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 210000002837 heart atrium Anatomy 0.000 description 1
- 230000001057 ionotropic effect Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229940039009 isoproterenol Drugs 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
Abstract
Derivatives of formula (I) (where R2 and R3 are H, or CH3, and either (a) R1 is 1,1-dimethyl-2-propynyl or allyl and R4 is cycloalkyl opt. mono- or polysubstd. by lower alkyl, phenyl opt. substd. by CH3, OCH3, F and/or Cl, chloroalkyl or alkyl, or (b) R1 is lower alkyl, 3-6C cycloalkyl or phenylalkyl and R4 is chloroalkyl or phenyl opt. substd. by CH3, OCH3, F and/or Cl) and their acid addn. salts, which have beta-adrenergic receptor blocking and antiarrhythmic activity and can be used for the treatment and prophylaxis of coronary diseases and for the treatment of disturbances in heart rhythm, are prepd. by reacting cpds. of formula (I; OCOR4 is OH) with anhydrides of (R4CO)2O in the presence of R4COOH.
Description
Die Erfindung betrifft ein Verfahren zur Herstellung neuer Indolderivate der Formel 1, worin R2 und R3 je für Wasserstoff oder Methyl stehen und entweder Rl Dimet- hyl-2-propinyl oder Allyl und R4 eine Cycloalkylgruppe, die durch eine oder mehrere niedere Alkylgruppen substituiert sein kann, einen Phenylrest, der einen oder mehrere Substituenten der Gruppe Methyl, Methoxy, Fluor oder Chlor tragen kann, eine Chloralkyl- oder Alkylgruppe bedeuten oder R, niederes Alkyl, eine Cycloalkylgruppe von 3 bis 6 Kohlenstoffatomen oder eine Phenylalkylgruppe und R4 einen Phenylrest, der einen oder mehrere Substituenten der Gruppe Methyl, Methoxy, Fluor oder Chlor tragen kann oder eine Chloralkylgruppe bedeuten und ihrer Säureadditionssalze.
Von den Verbindungen der Formel I sind diejenigen bevorzugt, worin der Rest Rl kompakt, insbesondere in a-Stellung zum Kohlenstoffatom verzweigt ist, wie z. B. die Isopropyl; sec. Butyl-, tert. Butyl-, tert. Pentyl-, 3-Pentylgruppe usw.
Falls R4 eine Alkylgruppe bedeutet, enthält diese vorzugsweise 1 bis 7 Kohlenstoffatome.
Steht R4 für eine Cycloalkylgruppe, so enthält diese vorzugsweise 3 bis 7 Kohlenstoffatome.
Allfällige Alkylsubstituenten dieser Cycloalkylgruppe enthalten insbesondere 1 bis 4 Kohlenstoffatome; von den Alkylsubstituenten ist die Methylgruppe bevorzugt, wie z. B. im 1 -Methylcyclohexyl.
Stellt R4 einen substituierten Phenylrest dar, so steht er insbesondere für p-Tolyl, p-Chlorphenyl, 3,4,5,-Trimethoxyphe- nyl, p-Fluorphenyl, 2,6Dichlorphenyl usw.
Erfindungsgemäss gelangt man zu den Verbindungen der Formel I und ihren Säureadditionssalzen, indem man Verbindungen der Formel II, worin R1, R2 und R3 obige Bedeutung besitzen, mit Säureanhydriden der Formel III, worin R4 obige Bedeutung besitzt, in Gegenwart der entsprechenden Säuren acyliert und die Verbindungen der Formel I als freie Basen oder als Säureadditionssalze gewinnt.
Aus den freien Basen lassen sich in bekannter Weise Säureadditionssalze herstellen und umgekehrt.
Praktisch geht man z. B. so vor, dass man Verbindungen der Formel II mit überschüssiger Säure R4COOH, worin R4 obige Bedeutung besitzt, versetzt und nach Zugabe eines Überschusses ihres Säureanhydrids während mehrerer Stunden bei Raum- oder leicht erhöhter Temperatur rührt.
Das so erhaltene Reaktionsgemisch kann z. B. aufgearbeitet werden, indem man es auf Eis giesst, mit Lauge oder Ammoniak alkalisch stellt und mit einem mit Wasser nicht mischbaren, unter den herrschenden Bedingungen inerten organischen Lösungsmittel wie z. B. Essigester, einem cyclischen oder offenkettigen Äther wie Diäthyläther usw., ausschüttelt.
Durch die anschliessende Behandlung mit Lauge oder Ammoniak wird ein allenfalls gebildeter Anteil an l-Acylie- rungsprodukt verseift; die Aufarbeitungsstufe soll selbstverständlich schonend erfolgen, da sonst auch die gebildete R4COOH-Estergruppe wieder gespalten würde.
Auch die Verbindungen der Formel 11 sind teilweise neu und können z. B. hergestellt werden, indem man Verbindungen der Formel IV, worin R2 und R3 obige Bedeutung besitzen, als Salz oder in Gegenwart einer Base mit Epihalohydrinen umsetzt und die so erhaltenen Reaktionsprodukte mit Aminen der Formel V, worin R, obige Bedeutung besitzt, kondensiert.
Die Verbindungen der Formel IV können z. B. durch hydrogenolytische Debenzylierung der entsprechenden 4-Benzyl oxyindol-Derivate hergestellt werden.
4-Benzyloxy-2-methylindol kann beispielsweise durch Umsetzung von 4-Benzyloxy-2-indolcarbonsäurechlorid mit einem Dialkylamin, anschliessende Reduktion des erhaltenen Amids mit z. B. Lithiumaluminiumhydrid zum 2-Dialkylaminomethyl4-benzyloxyindol, nachfolgende Quarternisierung des Stickstoffs und nochmalige Reduktion mit z. B. Lithiumaluminiumhydrid erhalten werden. Die 3-Methyl4-benzyloxyindol Derivate können beispielsweise durch Aminomethylierung von 4-Benzyloxyindol oder 4-Benzyloxy-2-methylindol unter den Bedingungen einer Mannich-Reaktion, nachfolgende Quarternisierung des Stickstoffs und anschliessende Reduktion mit z. B. Lithiumaluminiumhydrid hergestellt werden.
Soweit die Herstellung der Ausgangsprodukte nicht beschrieben wird, sind diese bekannt oder können nach an sich bekannten Verfahren bzw. analog zu den hier beschriebenen oder analog zu an sich bekannten Verfahren hergestellt werden.
Die neuen Verbindungen der Formel I oder ihre Säureadditionssalze sind in der Literatur bisher noch nicht beschrieben worden. Sie zeichnen sich durch interessante pharmakodynamische Eigenschaften aus und können daher als Heilmittel verwendet werden.
Die neuen Verbindungen zeigen am spontanschlagenden, isolierten Meerschweinchenvorhof eine Hemmung der positiv ionotropen Adrenalinwirkung, wobei diese antagonistische Wirkung bei Badkonzentrationen von 0,1 bis 2 mg/l auftritt.
Am narkotisierten Ganztier (Katze, Hund) führen sie zu einer lang anhaltenden, starken Hemmung der durch Isoproterenol [1 3,4-Dihydroxyphenyl > 2-isopropylaminoätha- nol] bedingten Tachycardie und Blutdrucksenkung. Die Verbindungen besitzen demnach eine Blockierwirkung auf die adrenergischen ss-Rezeptoren und können daher u. a. zur Prophylaxe und Therapie von Koronarerkrankungen verwendet werden. Aufgrund ihrer antiarrhythmischen Wirkung sind sie ausserdem zur Behandlung von Herzrhythmusstörungen geeignet.
Als Heilmittel können die neuen Verbindungen der Formel I bzw. ihre physiologisch verträglichen Säureadditionssalze allein oder in geeigneter Arzneiform mit pharmakologisch indifferenten Hilfsstoffen verabreicht werden.
In den nachfolgenden Beispielen, welche die Erfindung näher erläutern, ihren Umfang jedoch in keiner Weise einschränken sollen, erfolgen alle Temperaturangaben in Celsiusgraden und sind unkorrigiert.
EMI1.1
EMI2.1
Beispiel 1: 4 < 2-Benzoyloxy-3-isopropylaminopropoxy)indol
Zu einer auf 0" abgekühlten Suspension von 7,44 g 442-Hydroxy-3-isopropylaminopropoxy)indol und 66 g Benzoesäure in 100 ml Hexametapol tropft man eine Suspension von 7,14 g Benzoesäureanhydrid in 50 ml Hexametapol und rührt 24 Stunden bei 0 bis +5 . Anschliessend giesst man auf Eis, versetzt mit ca. 500 ml Äther und rührt 1 Stunde.
Unter guter Kühlung stellt man jetzt mit 100/obiger Ammoniak lösung alkalisch, trennt die ätherische Phase ab und trocknet sie über Magnesiumsulfat. Der Eindampfrückstand dieser ätherischen Phase wird an Kieselgel mit Methylenchlorid chromatographiert und die ölige Titelverbindung schliesslich in ihr Hydrogenoxalat überführt, Spiesse aus Äthanol/Essigester, (Smp. 178 bis 181").
Beispiel 2: 4{244-ChlorbutyryloxyS3-isopropylaminopropoxy]indol
Man verfährt analog Beispiel 1, verwendet jedoch anstatt Benzoesäure bzw. -anhydrid hier 4-Chlorbuttersäure bzw. deren Anhydrid. Das Hydrogenoxalat der Titelverbindung kristallisiert aus Äthanol/Benzol (Smp. 159 bis 161").
Beispiel 3: 4{342-Methyl-3-butin-2-ylamino)-2-pivaloyloxypropoxy]indol
Man verfährt analog Beispiel 1, verwendet jedoch anstatt Benzoesäure bzw. -anhydrid Pivalinsäure/-anhydrid. Das Hydrogenoxalat der Titelverbindung kristallisiert aus Äthanol/Benzol (Smp. 192" bis 194").
Beispiel 4: 4i2(2,6.Dichlorbenzoyloxy)-3-isopropylaminopropoxy]indol
Man verfährt analog Beispiel 1, verwendet jedoch anstatt Benzoesäure bzw. -anhydrid 2,6-Dichlorbenzoesäure bzw. deren Anhydrid. Das Hydrogenoxalat der Titelverbindung kristallisiert aus Eisessig/Essigester (Smp. 98 ).
The invention relates to a process for the preparation of new indole derivatives of the formula 1, in which R2 and R3 each represent hydrogen or methyl and either R1 is dimethyl-2-propynyl or allyl and R4 is a cycloalkyl group which can be substituted by one or more lower alkyl groups , a phenyl radical which can carry one or more substituents from the group methyl, methoxy, fluorine or chlorine, a chloroalkyl or alkyl group or R, lower alkyl, a cycloalkyl group of 3 to 6 carbon atoms or a phenylalkyl group and R4 a phenyl radical, the one or can carry several substituents from the group methyl, methoxy, fluorine or chlorine or denote a chloroalkyl group and their acid addition salts.
Of the compounds of the formula I, those are preferred in which the radical Rl is compactly branched, in particular in the a-position to the carbon atom, such as. B. the isopropyl; sec. butyl, tert. Butyl, tert. Pentyl, 3-pentyl, etc.
If R4 is an alkyl group, this preferably contains 1 to 7 carbon atoms.
If R4 stands for a cycloalkyl group, this preferably contains 3 to 7 carbon atoms.
Any alkyl substituents of this cycloalkyl group contain in particular 1 to 4 carbon atoms; of the alkyl substituents, the methyl group is preferred, such as e.g. B. im 1 -methylcyclohexyl.
If R4 represents a substituted phenyl radical, it stands in particular for p-tolyl, p-chlorophenyl, 3,4,5-trimethoxyphenyl, p-fluorophenyl, 2,6-dichlorophenyl, etc.
According to the invention, the compounds of the formula I and their acid addition salts are obtained by acylating compounds of the formula II in which R1, R2 and R3 have the above meaning with acid anhydrides of the formula III in which R4 has the above meaning in the presence of the corresponding acids and the Wins compounds of the formula I as free bases or as acid addition salts.
Acid addition salts can be prepared from the free bases in a known manner and vice versa.
In practice you go z. B. so that compounds of the formula II are mixed with excess acid R4COOH, in which R4 has the above meaning, and after adding an excess of its acid anhydride, the mixture is stirred for several hours at room or slightly elevated temperature.
The reaction mixture thus obtained can, for. B. be worked up by pouring it on ice, alkaline with alkali or ammonia and with a water-immiscible, inert under the prevailing conditions organic solvent such. B. ethyl acetate, a cyclic or open-chain ether such as diethyl ether, etc., shakes out.
The subsequent treatment with alkali or ammonia saponifies any portion of the 1-acylation product that may have formed; the work-up stage should of course be carried out gently, since otherwise the R4COOH ester group formed would also be cleaved again.
Some of the compounds of formula 11 are also new and can, for. B. be prepared by reacting compounds of the formula IV, in which R2 and R3 have the above meaning, as a salt or in the presence of a base with epihalohydrins and the reaction products thus obtained with amines of the formula V, in which R has the above meaning, condensed.
The compounds of formula IV can, for. B. be prepared by hydrogenolytic debenzylation of the corresponding 4-benzyl oxyindole derivatives.
4-Benzyloxy-2-methylindole can, for example, by reacting 4-benzyloxy-2-indolecarboxylic acid chloride with a dialkylamine, subsequent reduction of the amide obtained with z. B. lithium aluminum hydride to 2-dialkylaminomethyl4-benzyloxyindole, subsequent quaternization of the nitrogen and repeated reduction with z. B. lithium aluminum hydride can be obtained. The 3-methyl4-benzyloxyindole derivatives can, for example, by aminomethylation of 4-benzyloxyindole or 4-benzyloxy-2-methylindole under the conditions of a Mannich reaction, subsequent quaternization of the nitrogen and subsequent reduction with z. B. lithium aluminum hydride can be produced.
If the production of the starting products is not described, they are known or can be produced by processes known per se or analogously to those described here or analogously to processes known per se.
The new compounds of the formula I or their acid addition salts have not yet been described in the literature. They are distinguished by interesting pharmacodynamic properties, so they can be used as remedies.
The new compounds show an inhibition of the positively ionotropic adrenaline effect in the spontaneously beating, isolated guinea pig atrium, this antagonistic effect occurring at bath concentrations of 0.1 to 2 mg / l.
In the anesthetized whole animal (cat, dog) they lead to a long-lasting, strong inhibition of the tachycardia and lowering of blood pressure caused by isoproterenol [1 3,4-dihydroxyphenyl> 2-isopropylaminoethanol]. The compounds therefore have a blocking effect on the adrenergic receptors and can therefore u. a. be used for prophylaxis and therapy of coronary diseases. Due to their antiarrhythmic effect, they are also suitable for the treatment of cardiac arrhythmias.
The new compounds of the formula I or their physiologically tolerable acid addition salts can be administered as medicaments alone or in a suitable pharmaceutical form with pharmacologically inert adjuvants.
In the following examples, which explain the invention in more detail but are not intended to restrict its scope in any way, all temperatures are given in degrees Celsius and are uncorrected.
EMI1.1
EMI2.1
Example 1: 4 <2-Benzoyloxy-3-isopropylaminopropoxy) indole
A suspension of 7.14 g of benzoic anhydride in 50 ml of hexametapole is added dropwise to a suspension of 7.44 g of 442-hydroxy-3-isopropylaminopropoxy) indole and 66 g of benzoic acid in 100 ml of hexametapole and the mixture is stirred for 24 hours at 0 to The mixture is then poured onto ice, about 500 ml of ether are added and the mixture is stirred for 1 hour.
With good cooling, make alkaline with 100% ammonia solution, separate the ethereal phase and dry it over magnesium sulfate. The evaporation residue of this ethereal phase is chromatographed on silica gel with methylene chloride and the oily title compound is finally converted into its hydrogen oxalate, skewers of ethanol / ethyl acetate (melting point 178 to 181 ").
Example 2: 4 {244-chlorobutyryloxyS3-isopropylaminopropoxy] indole
The procedure is analogous to Example 1, but instead of benzoic acid or anhydride, 4-chlorobutyric acid or its anhydride is used here. The hydrogen oxalate of the title compound crystallizes from ethanol / benzene (melting point 159 to 161 ").
Example 3: 4 {342-methyl-3-butyn-2-ylamino) -2-pivaloyloxypropoxy] indole
The procedure is analogous to Example 1, but instead of benzoic acid or anhydride, pivalic acid / anhydride is used. The hydrogen oxalate of the title compound crystallizes from ethanol / benzene (melting point 192 "to 194").
Example 4: 4i2 (2,6-dichlorobenzoyloxy) -3-isopropylaminopropoxy] indole
The procedure is analogous to Example 1, but instead of benzoic acid or anhydride, 2,6-dichlorobenzoic acid or its anhydride is used. The hydrogen oxalate of the title compound crystallizes from glacial acetic acid / ethyl acetate (melting point 98).
Claims (1)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH18271 | 1971-01-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH545783A true CH545783A (en) | 1974-02-15 |
Family
ID=4181133
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH18271A CH545783A (en) | 1971-01-07 | 1971-01-07 | Novel indole derivs - prepn by reacting 4-(2-hydroxy-3-isopropylaminopropoxy) indoles and acid anhy-drides |
Country Status (1)
| Country | Link |
|---|---|
| CH (1) | CH545783A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5223073A (en) * | 1975-08-15 | 1977-02-21 | Sandoz Ag | Improvement of organic compound |
-
1971
- 1971-01-07 CH CH18271A patent/CH545783A/en not_active IP Right Cessation
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5223073A (en) * | 1975-08-15 | 1977-02-21 | Sandoz Ag | Improvement of organic compound |
| DK152120B (en) * | 1975-08-15 | 1988-02-01 | Sandoz Ag | ANALOGY PROCEDURE FOR THE PREPARATION OF 4- (2-ACYLOXY-3-TERT.BUTYLAMINOPROPOXY) -INDEAL DERIVATIVES |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AT368125B (en) | METHOD FOR PRODUCING NEW 9-AMINOALKYL FLUORENES AND THEIR SALTS | |
| DE1518452C3 (en) | 4 substituted 2 benzhydryl 2 butanol derivatives and process for their preparation | |
| CH545783A (en) | Novel indole derivs - prepn by reacting 4-(2-hydroxy-3-isopropylaminopropoxy) indoles and acid anhy-drides | |
| DE2427272C3 (en) | 1- (2- (β-Naphthyloxy) ethyl) -3-methyl-pyrazolone- (5), method and use as an antithrombotic | |
| DE2520131C3 (en) | 1,1-disubstituted octahydro-indolo [2,3-a] quinolizines and processes for their preparation | |
| DE2331721A1 (en) | PROCESS FOR PRODUCING NEW HETEROCYCLIC COMPOUNDS | |
| CH545784A (en) | Beta blocking and anti-arrhythmic indole derivs - prepd by catalytic de-benzylation of 4-(3-benzyl aminopropoxy) indoles | |
| DE2148553A1 (en) | Process for the preparation of new heterocyclic compounds | |
| CH535763A (en) | 4-(2-acyloxy-3-amino-propoxy)-indoles - as beta-adrenergic blocking agents | |
| CH547282A (en) | Indolyloxypropanolamines for coronary disease therapy - have long-lasting beta-adrenergic receptor blocking and antiarrhythmic activity | |
| CH546742A (en) | PROCESS FOR THE PRODUCTION OF METHOXYAMINE DERIVATIVES AND THEIR SALT. | |
| DE1252209B (en) | ||
| AT238181B (en) | Process for the preparation of new pyrrolidine compounds | |
| DE2404924A1 (en) | ERGOLINE DERIVATIVES | |
| DE2624967A1 (en) | NEW ORGANIC COMPOUNDS, THEIR PRODUCTION AND USE | |
| CH511840A (en) | Analgesic 2-benzoyl-indole derivs | |
| CH535764A (en) | Indolyloxypropanolamine esters - with beta-blocking activity | |
| AT225197B (en) | Process for the preparation of the new N- [p-3,3-disubstituted-1-azetidinylethoxy) benzyl] -3,4,5-trimethoxybenzamides | |
| DE1900948C (en) | Cis- and trans-2-methyl-5- (3, 4, S-trimethoxybenzamidoJ-decahydroisoquinoline | |
| DE2500919C3 (en) | 5- (l-Allyl-2-pyrrolidinylmethylaminocarbonyl) -6-methoxy-benzotriazole and its pharmaceutically acceptable addition salts with acids | |
| CH547281A (en) | 4 and 7-Aminopropoyx-oxindole derivs - useful as anti-arrhythmics and beta-adrenergic blockers | |
| CH529755A (en) | 4-benzoyl-4-hydroxy-3-phenyl-piperidine - with hypolipaemic activity | |
| CH544089A (en) | Indole derivs - with pharmacodynamic activity | |
| DE1235922B (en) | Process for the preparation of new N-substituted 4-phenyl-piperidine-4-carbon-acidic ethyl ester compounds | |
| CH526546A (en) | 3-phenyl-4-hydroxy-4-benzoylpiperidines - with hypolipaemic activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PL | Patent ceased |